A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00481091 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: ABT-263

Sponsor

AbbVie

Collaborators

[object Object]